Expression of DEK in Oral Squamous Cell Carcinoma

다국어 초록 (Multilingual Abstract)

Human DEK gene on chromosome 6p encodes a 43kD nuclear phospoprotein that was originally identified as part of a fusion protein found in a subset of acute myeloid leukemia carrying a t(6;9) translocation. Although DEK upregulation has been described in a number of human malignancies and was significantly associated with high histologic grade, lymph node metastasis and/or advanced clinical stage, no previous report has evaluated the expression of DEK protein and its clinical significance in oral squamous cell carcinoma (OSCC). Our aims were to determine DEK expression in tissue samples of normal oral mucosa and OSCC by immunohistochemistry, to analyze the correlation between DEK expression and clinicopathological parameters, and to evaluate the value of DEK as a prognostic marker for patient’s survival. Ten normal oral mucosa, 10 epithelial dysplasia, and 60 OSCC samples were studied by immunohistochemistry. DEK expression tended to increase through the full thickness of epithelium in the dysplastic mucosa when compared with those in normal oral mucosa. High expression of DEK protein (score ≥ 2) was found in 68.3% of OSCC cases. Statistical analysis revealed that DEK overexpression in OSCC was positively correlated with high histologic grade (p=0.001), lymph node metastasis (p=0.003), and advanced clinical stage (p=0.039). In the Kaplan-Meier survival analysis, DEK overexpression was significantly associated with decreased overall survival in patients with OSCC (p=0.019). Our results suggest that DEK overexpression may be a reliable marker to predict the clinical outcome in OSCC.

참고문헌 (Reference)

1 von Lindern M, "The translocation(6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA" 12 : 1687-1697, 1992

2 Kroes RA, "The identification of novel therapeutic targets for the treatment of malignant brain tumors" 156 : 191-198, 2000

3 Wise-Draper TM, "Overexpre-ssion of the cellular DEK protein promotes epithelial transformation in vitro and in vivo" 69 : 1792-1799, 2009

4 Khodadoust MS, "Melanoma proliferation and chemoresistance controlled by the DEK oncogene" 69 : 6405-6413, 2009

5 Lin L, "Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer" 9 : e111260-, 2014

6 Nagpal JK, "Identification of differentially expressed genes in tobacco chewing-mediated oral cancer by differential display-polymerase chain reaction" 37 : 658-664, 2007

7 Kondoh N, "Identification and characterization of genes associated with human hepatocellular carcinogenesis" 59 : 4990-4996, 1999

8 Piao J, "High expression of DEK predicts poor prognosis of gastric adenocarcinoma" 9 : 67-, 2014

9 Grasemann C, "Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma" 24 : 6441-6449, 2005

10 Ferlay J, "GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11" International Agency for Research on Cancer

11 Evans AJ, "Defining a 0.5-mb region of genomic gain on chromosome 6p22in bladder cancer by quantitative-multiplex polymerase chain reaction" 164 : 285-293, 2004

12 Wise-Draper TM, "DEK proto-oncogene expression interferes with the normal epithelial differentiation program" 174 : 71-81, 2009

13 Liu S, "DEK overexpression is correlated with the clinical features of breast cancer" 62 : 176-181, 2012

14 Wu Q, "DEK overexpression in uterine cervical cancers" 58 : 378-382, 2008

15 Lin L, "DEK over expression as an independent biomarker for poor prognosis in colorectal cancer" 13 : 366-, 2013

16 Carro MS, "DEK expression is controlled by E2F and deregulated in diverse tumor types" 5 : 1202-1207, 2006

17 Patel RM, "DEK expression in Merkel cell carcinoma and small cell carcinoma" 39 : 753-757, 2012

18 Han S, "Clinicopathological significance of DEK overexpression in serous ovarian tumors" 59 : 443-447, 2009

19 Wise-Draper TM, "Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions" 26 : 7506-7519, 2006